AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Newswise

Published November 4, 2026 · Updated November 5, 2026

Psychedelic After-Effects May Offer a Window into Psychotic Symptoms | Newswise

Read the full story at Newswise

Biotech · Cancer · Coronavirus/COVID-19 · Clinical Trials · Diabetes · Genetics ... Psychedelic After-Effects May Offer a Window into Psychotic Symptoms.

Post on X

Share this story

Surfaced by this Google Alert

Psychedelic biotech